22 June 2018 - The pharma industry has called for European member states’ national drug value assessment bodies to be abolished if a system to limit drug prices comes into effect across the EU.

At the beginning of the year, the European Commission proposed a binding regulation on health technology assessment (HTA).

While pricing is a matter decided by individual member states, the regulation would provide the basis for permanent EU-level cooperation in HTA.

Read Pharmaphorum article